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Abstract 
Pyogenic  granuloma,  also  known  as  lobular  capillary  hemangioma,  is  a  common  benign 
vascular proliferative lesion that can present at any age on the skin or mucous membranes. 
Most  lesions  do  not  exceed  2  cm,  but  there  are  a  handful  of  giant  cutaneous  pyogenic 
granulomas that have been reported, often in individuals with underlying immune dysfunc-
tion. Here, we report the first giant pyogenic granuloma in a patient with a hematological 
malignancy, chronic lymphocytic leukemia.  © 2014 S. Karger AG, Basel 
Introduction 
Pyogenic granuloma is a common benign vascular proliferative lesion of the skin and 
mucosa. First described in 1897 by Poncet and Dor, it was thought to represent a reactive 
response to an unidentified bacterium given the florid granulation tissue and inflammation 
on histology. However, no causal bacterium was identified, and in 1980, it was proposed that 
pyogenic  granuloma  was  instead  a  vascular  proliferative  lesion,  which  could  be  best 
visualized by histology of the lesion’s base [1]. Hence, the alternative name for pyogenic 
granuloma, lobular capillary hemangioma, was introduced. Here, we present a case of a giant 
cutaneous pyogenic granuloma in a patient with chronic lymphocytic leukemia (CLL).  
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Case Report 
A 52-year-old woman with CLL presented with a 1-month history of a rapidly expanding 
mass on her forearm. She  reported  intermittent  bleeding and crusting, but denied pain, 
pruritus  or  frank  pus.  A  week  prior  to  the  development  of  the  mass,  she  had  begun 
chemotherapy for CLL with rituximab, bendamustine and lenalidomide requiring multiple 
blood draws from her arm. Her medical history was otherwise unremarkable. She had no 
recent travel, animal exposures or new medications aside from chemotherapy. 
Physical examination revealed a 4.7 × 3.7 cm pedunculated, firm mass with a fleshy, 
erythematous stalk and a peripheral border of hemorrhagic crust on the volar surface of her 
left forearm (fig. 1a). Laboratory  results  were significant  for pancytopenia with a  white 
blood cell count of 800 cells/µl (16% neutrophils). Punch biopsy of the stalk was performed, 
which showed a histological picture most suggestive of reactive changes to trauma (fig. 1b). 
However, given concern that the biopsy was not representative of the entire lesion, full 
excision was recommended. The excision specimen demonstrated a polypoid lesion with 
vaguely lobulated vascular proliferation (fig. 1c). High magnification showed a lobulated 
proliferation of capillary-sized vessels (fig. 1d). 
Postoperatively, the patient experienced wound dehiscence in the setting of persistent 
neutropenia. She was treated with wet-to-dry dressings, and her chemotherapy was held. 
Subsequently,  her  white  blood  cell  count  normalized,  and  her  wound  healed  without  a 
revised closure or skin graft. 
Discussion 
Pyogenic  granuloma  often  presents  as  a  solitary,  red-purple  nodule  that  undergoes 
rapid growth over weeks to months. Mucosal lesions are more common in women (2.6:1), 
particularly during pregnancy, pointing to estrogen as an important driving factor in their 
pathogenesis [2]. In contrast, cutaneous lesions have a slight male predominance (1.2:1) and 
are  commonly  found  on  the  trunk  and  upper  extremities  in  adults  [2].  This  divergent 
epidemiology of mucosal and cutaneous pyogenic granulomas suggests that these lesions 
may have partially distinct routes of pathogenesis. 
In our case, the patient’s pyogenic granuloma was 4.7 × 3.7 cm, which far exceeds the 
previously published average size of pyogenic granulomas, which ranges from 0.65 to 1.1 cm 
[3, 4]. There are a handful of giant cutaneous pyogenic granulomas that have been reported 
in the past, often in individuals with underlying immune dysfunction, but never in a patient 
with CLL [5, 6]. 
In making the diagnosis of pyogenic granuloma, it is important to exclude a more sinis-
ter  diagnosis,  such  as  amelanotic  melanoma,  metastatic  carcinoma,  leukemia  cutis, 
squamous cell carcinoma, angiosarcoma, bacillary angiomatosis and fungal infection, which 
can be done using light microscopy. In our patient, given her history of progressive CLL, it 
was important to exclude leukemia cutis and squamous cell carcinoma, particularly given 
her eight-fold increased risk for developing a squamous cell carcinoma with a poor outcome 
[7, 8]. Thus, heightened suspicion for these diagnoses contributed to the decision to pursue 
excisional  biopsy  despite  her  inconclusive  punch  biopsy  to  definitely  exclude  these 
diagnoses. The characteristic histopathological findings of pyogenic granulomas include a 
lobular arrangement of proliferating capillaries separated by myxoid or fibrous connective 
tissue septa. Often, this architecture is obscured by edema, hemorrhage, inflammation and 
ulceration,  much  like  our  patient’s  pathology  showed.  Immunohistochemistry  is  rarely  
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performed, but would reveal positive staining for vascular markers CD31, CD34 and factor 
VIII.  Glucose  transporter  1  staining  is  negative,  thereby  distinguishing  it  from  juvenile 
hemangioma. 
There are numerous treatments available for pyogenic granulomas, including surgical 
and medical options [9]. Generally, the choice of treatment depends on the location, size and 
shape  of  the  underlying  lesion.  Certain  practices  are  associated  with  lower  rates  of 
recurrence, including surgical excision and topical imiquimod therapy, but there are very 
few randomized controlled trials directly comparing available therapies [9]. 
At  present,  the  pathogenesis  of  pyogenic  granuloma  is  unknown.  Reported  triggers 
include antecedent trauma, pregnancy and certain drugs, including acitretin, HIV protease 
inhibitors, EGFR  inhibitors,  docetaxel, capecitabine and  rituximab  [10,  11]. Interestingly, 
drug-associated pyogenic granulomas tend to have a periungual and subungual distribution 
[10]. Recent insights from gene expression profiling identify FLT4 (a specific VEGF receptor), 
the nitric oxide pathway and vascular injury and repair pathways as specifically upregulated 
in  pyogenic  granulomas  compared  to  other  vascular  proliferative  lesions  [12].  How  the 
molecular underpinnings connect to the diverse set of reported triggers remains unclear. 
This case highlights an unusual presentation of a pyogenic granuloma given the shear 
size  of  the  lesion.  Contributing  factors  may  include  immune  dysfunction  due  to  CLL, 
persistent  neutropenia  and  trauma  sustained  due  to  multiple  blood  draws  to  her  left 
forearm. Although there is one reported case of multiple, small periungual and subungual 
pyogenic  granulomas  following  rituximab  exposure,  the  appearance  and  distribution  of 
these lesions were unlike our patient’s, making rituximab a less likely contributing factor 
[11]. However, given the small number of giant pyogenic granulomas reported to date, it is 
difficult to exclude any associations with medications. Interestingly, in the handful of giant 
cutaneous  pyogenic  granulomas  reported,  the majority of hosts had underlying immune 
dysfunction,  which  may  be  an  important  risk  factor  for  the  development  of  such  large 
pyogenic granulomas. 
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Fig. 1. a The pedunculated mass on the left volar forearm. b Histopathology of the punch biopsy showed 
slightly acanthotic epidermis with dermal fibrosis and vascular proliferation with mixed inflammatory 
infiltrate, most consistent with reactive changes to trauma (hematoxylin-eosin, original magnification ×4). 
c Although no evidence of malignancy was identified in the biopsy specimen, excision was recommended 
given the large size of the lesion and clinical suspicion for malignancy that was not visualized on the 
biopsy. The excision specimen demonstrated a large ulcerated, polypoid lesion with dermal edema and 
hemorrhage and vaguely lobulated vascular proliferation (hematoxylin-eosin, original magnification ×10). 
d High magnification of the excisional specimen demonstrated lobulated proliferation of capillary-sized 
vessels  with  small  indistinct  lumina.  No  cytological  atypia  was  present  (hematoxylin-eosin,  original 
magnification ×40). 
 